cilostazol / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 86 Diseases   33 Trials   33 Trials   1474 News 


«12...6789101112131415161718»
  • ||||||||||  cilostazol / Generic mfg.
    Trial completion, Phase classification, Trial completion date, Trial primary completion date:  CAS-CARE: Carotid Artery Stenting With Cilostazol Addition for Restenosis (clinicaltrials.gov) -  Oct 16, 2019   
    P=N/A,  N=707, Completed, 
    Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | Trial completion date: Mar 2019 --> Sep 2019 | Trial primary completion date: Mar 2017 --> Mar 2019
  • ||||||||||  hexasodium phytate (SNF472) / Sanifit
    SNF472, a New Therapeutic Approach to Improve Outcomes in CKD Patients with Peripheral Artery Disease (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4492;    
    The inhibition of calcification in SNF472 treated animals was associated with significant higher limb blood perfusion compared to vehicle or Cilostazol (1.28 and 1.37-fold higher, respectively at D12: p< 0.001) and translated into significant improvement in limbs walking ability compared to vehicle (515±114 meters vs 334±187 meters, respectively: p<0.05). Conclusion Our results evidence that SNF472 may present a promising new therapeutic approach to treat PAD associated with high vascular calcification such as in CKD and HD patients Funding Commercial Support
  • ||||||||||  Trial completion date, Trial primary completion date:  Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm (clinicaltrials.gov) -  Oct 10, 2019   
    P4,  N=176, Recruiting, 
    Oral administration of cilostazol can be a therapeutic option for patients with sinus bradycardia following HT, who need positive chronotropic support. Trial completion date: Jul 2019 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Oct 2020
  • ||||||||||  Bosulif (bosutinib) / Pfizer, Pletal (cilostazol) / Otsuka, Tasigna (nilotinib) / Novartis, Inhibikase
    Clinical, Journal:  A case of recurrent cerebral infarction during treatment with oral tyrosine kinase inhibitors for chronic myelogenous leukemia (Pubmed Central) -  Oct 8, 2019   
    He was initiated on clopidogrel and bosutinib instead of nilotinib...Carotid artery stenting of the left ICA was performed in February 2018, and clopidogrel was replaced by cilostazol to provide a drug-induced rush...In recent years, several case reports suggest that tyrosine kinase inhibitors (TKIs) are associated with progressive artery stenosis and cause cerebral infarction. Brain imaging tests should be conducted to evaluate arterial stenosis progression for patients with a history of taking TKI when an arterial vascular event occurs.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. (Pubmed Central) -  Sep 26, 2019   
    Adjunctive cilostazol therapy tailored to CYP2C19 genotype seemed useful in AMI patients with the CYP2C19 reduced-function allele. This study indicates that the risk minimization measures implemented by the EMA for the use of cilostazol have been effective in all European countries studied, except for smoking cessation before initiating cilostazol, which remains an area of improvement.
  • ||||||||||  Pletal (cilostazol) / Otsuka, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
    Journal:  Drug Repositioning for Alzheimer's Disease (Pubmed Central) -  Sep 22, 2019   
    This is in line with the recent emphasis that AD should be studied as a complex multifactorial disorder, not dominated by one dominant biological factor such as beta-amyloid, and without disregarding any relevant pathologic factor, such as vascular dysregulation. It is strongly expected that drug repositioning approaches will create a paradigm shift in treatment approaches for AD patients.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  Outcomes with cilostazol after endovascular therapy of peripheral artery disease. (Pubmed Central) -  Sep 18, 2019   
    We conclude that the use of cilostazol after EVT of femoropopliteal and iliac lesions is associated with improved primary patency and lower risk of major amputation and TLR. The favorable impact of cilostazol is independent of the use of warfarin.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Review, Journal:  PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment. (Pubmed Central) -  Aug 30, 2019   
    In this review, we present a brief summary of cAMP signaling and different PDE inhibitors, followed by a discussion of the pharmacological and physiological role of PDE3 inhibitors. In this context, we discuss the repurposing of a PDE3 inhibitor, cilostazol, as a potential treatment for age-related cognitive impairment based on recent research.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  Meningeal contribution to migraine pain: a magnetic resonance angiography study. (Pubmed Central) -  Aug 23, 2019   
    ...To test this hypothesis, we measured circumference changes of cranial arteries in patients with cilostazol-induced unilateral migraine without aura using 3 T high resolution magnetic resonance angiography...Magnetic resonance angiography scans were performed at baseline, migraine onset, after sumatriptan, and ≥27 h after migraine onset...In conclusion, onset of migraine is associated with increase in middle meningeal artery circumference specific to the head pain side. Our findings suggest that vasodilation of the middle meningeal artery may be a surrogate marker for activation of dural perivascular nociceptors, indicating a meningeal site of migraine headache.10.1093/brain/awy300_video1awy300media15983750185001.
  • ||||||||||  aspirin / Generic Mfg., Pletal (cilostazol) / Otsuka
    Impact of Triple Antiplatelet Therapy on Multivessel Coronary Artery Intervention in Acute Myocardial Infarction Patients (Zone 4, Science and Technology Hall) -  Aug 21, 2019 - Abstract #AHA2019AHA_7570;    
    However, there are limited data concerning the impact of triple antiplatelets (including cilostazol) on short and long term clinical outcomes following multivessel PCI in AMI setting... In this study, triple antiplatelet therapy following multivessel PCI in AMI was associated with reduced risk of adverse clinical outcomes including incidence of cardiac death, revascularization, stent thrombosis, stroke, stent thrmbosis and total MACE as compared with dual antiplatelet therapy despite of worse clinical and angiographic characteristics at 30 days and up to 1 year.
  • ||||||||||  Pletal (cilostazol) / Otsuka, Esbriet (pirfenidone) / Shionogi, Roche
    In vitro Drug Screening Model for Cardiac Fibrosis Using Human Induced Pluripotent Stem Cell Derived Cardiac Tissue Provides Drug Repositioning of Anti-fibrotic Drugs for Cardiac Fibrosis (Zone 1, Science and Technology Hall) -  Aug 21, 2019 - Abstract #AHA2019AHA_5413;    
    Then we assessed the anti-fibrotic candidate drugs (camostat mesilate (Cs), pirfenidone (Pf), and cilostazol (Cz)) which have been already proved to have clinical efficacy in fibrosis based diseases such as idiopathic pulmonary fibrosis by using CTS stimulated by TGF-β, resulting that addition of Cs or Pf significantly decreased the expression of CF-ECM and improved the contractile/relaxation property. CTS generated by iPSC-CM and non-CM modulated by fibrotic stimulation closely simulated fibrosis based-distressed myocardium and showed precise response to anti-fibrotic agents in vitro , which propose expected therapeutic response to in vivo HF model, suggesting useful tool for anti-fibrotic medication screening as drug repositioning.
  • ||||||||||  aspirin / Generic Mfg., Pletal (cilostazol) / Otsuka
    STUDY ON COMPLICATIONS OF EUS-FNA IN CASES TAKING ANTITHROMBOTIC DRUGS (Poster Exhibition - Hall 7) -  Aug 18, 2019 - Abstract #UEGW2019UEGW_3252;    
    Hemorrhaging was more frequent in the aspirin or cilostazol replacement group than in the other groups but improved with conservative treatment. Even in patients taking antithrombotic drugs, the risk of bleeding is low, and it may be possible to safely perform EUS-FNA.
  • ||||||||||  cilostazol / Generic mfg.
    Trial completion date, Trial primary completion date:  SILOAM: Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients (clinicaltrials.gov) -  Aug 14, 2019   
    P4,  N=951, Recruiting, 
    Furthermore, CS can be beneficial as an add-on drug with the conventional treatments of colitis. Trial completion date: Feb 2019 --> Sep 2019 | Trial primary completion date: Feb 2019 --> Sep 2019
  • ||||||||||  aspirin / Generic mfg., cilostazol / Generic mfg.
    Trial completion date, Trial primary completion date:  Challenge: Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease (clinicaltrials.gov) -  Aug 8, 2019   
    P4,  N=255, Active, not recruiting, 
    Trial completion date: Feb 2019 --> Sep 2019 | Trial primary completion date: Feb 2019 --> Sep 2019 Trial completion date: Oct 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis. (Pubmed Central) -  Aug 8, 2019   
    Trial completion date: Oct 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 This small comparative study suggests that administering cilostazol for ISR lesions after femoropopliteal stenting reduces recurrent ISR.
  • ||||||||||  sildenafil / Generic mfg.
    Enrollment open:  OxHARP: Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial (clinicaltrials.gov) -  Aug 2, 2019   
    P2,  N=75, Recruiting, 
    Thus, the formulations can be used interchangeably in clinical practice. Not yet recruiting --> Recruiting
  • ||||||||||  Levitra (vardenafil) / Bayer, Pletal (cilostazol) / Otsuka
    Biomarker, Preclinical, Journal:  Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity. (Pubmed Central) -  Jul 6, 2019   
    Vardenafil and cilostazol significantly improved endothelial integrity biomarkers in vivo supported with histopathological findings in addition to improved vasorelaxation in vitro. Apart from their known PDE inhibition, up-regulation of vascular AMPK and eNOS coupled with down-regulation of Ang-II, ET-1, P-selectin, VCAM-1 and MMP-2 may explain vardenafil and cilostazol protective effect against RA/DM-co-morbidity-induced endothelial dysfunction and vascular reactivity defects.
  • ||||||||||  aspirin / Generic mfg., cilostazol / Generic mfg.
    Trial completion date, Trial primary completion date:  CILO-PER: Cilostazol Following Peripheral Endovascular Procedures (clinicaltrials.gov) -  Jul 5, 2019   
    P3,  N=200, Recruiting, 
    Apart from their known PDE inhibition, up-regulation of vascular AMPK and eNOS coupled with down-regulation of Ang-II, ET-1, P-selectin, VCAM-1 and MMP-2 may explain vardenafil and cilostazol protective effect against RA/DM-co-morbidity-induced endothelial dysfunction and vascular reactivity defects. Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Jun 2019 --> Dec 2020
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model. (Pubmed Central) -  Jun 19, 2019   
    Moreover, inhibition of MRP4 induced by cilostazol enhances aspirin-induced antiplatelet effects and reduces HARPR. Rosuvastatin combined with cilostazol therapy can greatly improve the anti-inflammatory effect of monotherapies, resulting in reduced mortality of mice; thus, we propose the potential of use of this combination therapy as anti-TNF agent.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Review, Journal:  Pharmacological Potential of Cilostazol for Alzheimer's Disease. (Pubmed Central) -  Jun 14, 2019   
    Further underscoring the potential of CSZ for AD treatment, we recently described the inhibitory effects of CSZ on Aβ oligomerization and aggregation in vitro. In this review, we discuss the possibility of CSZ as a potential disease-modifying therapy for the prevention or delay of AD.
  • ||||||||||  cilostazol / Generic mfg., sumatriptan succinate / Generic mfg.
    Trial completion:  The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache (clinicaltrials.gov) -  Jun 6, 2019   
    P=N/A,  N=30, Completed, 
    In this review, we discuss the possibility of CSZ as a potential disease-modifying therapy for the prevention or delay of AD. Recruiting --> Completed
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Clinical, PK/PD data, Journal:  Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects. (Pubmed Central) -  May 31, 2019   
    However, the effects of a single dose of simvastatin on serum lipid profiles were not affected notably when simvastatin was coadministered with cilostazol. Multiple doses of cilostazol increased the systemic exposure of simvastatin and simvastatin acid following a single dose of simvastatin.